Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-Line or Second-Line Therapy

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed ovarian stromal cancer not amenable to surgery

- Granulosa cell tumor

- Granulosa cell theca cell tumor

- Sertoli-Leydig cell tumor (androblastoma)

- Gynandroblastoma

- Unclassified sex cord stromal tumor

- Sex cord tumor with annular tubules

- Steroid (lipid) cell tumor

- Recurrent disease after no more than 1 prior chemotherapy regimen

- Measurable disease

- At least 1 cm in diameter

PATIENT CHARACTERISTICS:

Age:

- Not specified

Performance status:

- GOG 0-2

Life expectancy:

- Not specified

Hematopoietic:

- WBC at least 3,000/mm^3

- Granulocyte count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- Bilirubin no greater than 1.5 times normal

- SGOT no greater than 3 times normal

Renal:

- Creatinine no greater than 2.0 mg/dL

Other:

- Not pregnant

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other prior invasive malignancy in past 5 years except nonmelanoma skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- See Disease Characteristics

Endocrine therapy:

- Not specified

Radiotherapy:

- No prior radiotherapy to study lesion

Surgery:

- See Disease Characteristics